NovAccess Global Inc. (OTCMKTS:XSNX – Get Free Report) saw a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 400 shares, a decline of 99.4% from the March 31st total of 65,900 shares. Based on an average daily volume of 1,568,900 shares, the short-interest ratio is presently 0.0 days.
NovAccess Global Trading Down 12.5 %
XSNX stock traded down $0.00 during trading on Thursday, reaching $0.01. 1,222,515 shares of the stock were exchanged, compared to its average volume of 683,010. The business has a 50 day moving average price of $0.01 and a 200-day moving average price of $0.03. NovAccess Global has a 1 year low of $0.01 and a 1 year high of $0.22. The firm has a market capitalization of $245,000.00, a price-to-earnings ratio of -0.07 and a beta of 1.51.
NovAccess Global (OTCMKTS:XSNX – Get Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $0.01 earnings per share for the quarter.
NovAccess Global Company Profile
NovAccess Global Inc, a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.
Read More
- Five stocks we like better than NovAccess Global
- 3 Healthcare Dividend Stocks to Buy
- Hasbro’s Management Made All the Right Calls This Quarter
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- About the Markup Calculator
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for NovAccess Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovAccess Global and related companies with MarketBeat.com's FREE daily email newsletter.
